Axillary Hyperhidrosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major axillary hyperhidrosis markets reached a value of US$ 1.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.1 Billion by 2034, exhibiting a growth rate (CAGR) of 5.53% during 2024-2034.
The axillary hyperhidrosis market has been comprehensively analyzed in IMARC's new report titled "Axillary Hyperhidrosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Axillary hyperhidrosis, also called excessive underarm sweating, is a medical condition characterized by abnormal and uncontrollable production of sweat in the armpit region. This disorder can significantly impact a patient's quality of life, leading to embarrassment, social anxiety, and discomfort. The symptoms of the ailment include persistent and profuse sweating in the armpits, even in cool or relaxed conditions, which may result in unpleasant body odor and damp clothing. Diagnosing axillary hyperhidrosis involves a comprehensive evaluation by a healthcare professional. The doctor will typically conduct a physical examination and review the patient's clinical history to rule out any underlying medical problems that could be contributing to excessive sweating. Moreover, various other workups, such as the starch-iodine test, are utilized to confirm the diagnosis and assess the extent of sweat production in the affected area. Early detection and appropriate intervention of the disease can aid patients in leading a more comfortable and confident life.
The rising prevalence of endocrine disorders, which can result in overactivation of the sweat glands in the armpits, leading to excessive and uncontrollable sweating in the affected region, is primarily driving the axillary hyperhidrosis market. In addition to this, the increasing incidence of inadequate treatment or lack of proper immunization against the condition, that can further enhance the risk of complications and exacerbate the demand for effective solutions, is also creating a positive outlook for the market. Moreover, the widespread adoption of several effective drugs, including topical antiperspirants, iontophoresis, botulinum toxin injections, etc., to alleviate the symptoms and manage the underlying causes of axillary hyperhidrosis is further bolstering the market growth. Apart from this, the rising usage of innovative treatments, such as neuromuscular blockers, since they work by interrupting nerve impulses at the affected myoneural junction to minimize excessive sweating, muscle spasms, and discomfort in individuals suffering from the illness, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of axillary hyperhidrosis immune globulin (AHIG) therapy, which aims to neutralize bacterial toxins and prevent their harmful effects by providing immediate passive immunity against pathogens, is expected to drive the axillary hyperhidrosis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the axillary hyperhidrosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for axillary hyperhidrosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the axillary hyperhidrosis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the axillary hyperhidrosis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the axillary hyperhidrosis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current axillary hyperhidrosis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the axillary hyperhidrosis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the axillary hyperhidrosis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the axillary hyperhidrosis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of axillary hyperhidrosis across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of axillary hyperhidrosis by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of axillary hyperhidrosis by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with axillary hyperhidrosis across the seven major markets?
What is the size of the axillary hyperhidrosis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of axillary hyperhidrosis?
What will be the growth rate of patients across the seven major markets?
Axillary Hyperhidrosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for axillary hyperhidrosis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the axillary hyperhidrosis market?
What are the key regulatory events related to the axillary hyperhidrosis market?
What is the structure of clinical trial landscape by status related to the axillary hyperhidrosis market?
What is the structure of clinical trial landscape by phase related to the axillary hyperhidrosis market?
What is the structure of clinical trial landscape by route of administration related to the axillary hyperhidrosis market?
The axillary hyperhidrosis market has been comprehensively analyzed in IMARC's new report titled "Axillary Hyperhidrosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Axillary hyperhidrosis, also called excessive underarm sweating, is a medical condition characterized by abnormal and uncontrollable production of sweat in the armpit region. This disorder can significantly impact a patient's quality of life, leading to embarrassment, social anxiety, and discomfort. The symptoms of the ailment include persistent and profuse sweating in the armpits, even in cool or relaxed conditions, which may result in unpleasant body odor and damp clothing. Diagnosing axillary hyperhidrosis involves a comprehensive evaluation by a healthcare professional. The doctor will typically conduct a physical examination and review the patient's clinical history to rule out any underlying medical problems that could be contributing to excessive sweating. Moreover, various other workups, such as the starch-iodine test, are utilized to confirm the diagnosis and assess the extent of sweat production in the affected area. Early detection and appropriate intervention of the disease can aid patients in leading a more comfortable and confident life.
The rising prevalence of endocrine disorders, which can result in overactivation of the sweat glands in the armpits, leading to excessive and uncontrollable sweating in the affected region, is primarily driving the axillary hyperhidrosis market. In addition to this, the increasing incidence of inadequate treatment or lack of proper immunization against the condition, that can further enhance the risk of complications and exacerbate the demand for effective solutions, is also creating a positive outlook for the market. Moreover, the widespread adoption of several effective drugs, including topical antiperspirants, iontophoresis, botulinum toxin injections, etc., to alleviate the symptoms and manage the underlying causes of axillary hyperhidrosis is further bolstering the market growth. Apart from this, the rising usage of innovative treatments, such as neuromuscular blockers, since they work by interrupting nerve impulses at the affected myoneural junction to minimize excessive sweating, muscle spasms, and discomfort in individuals suffering from the illness, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of axillary hyperhidrosis immune globulin (AHIG) therapy, which aims to neutralize bacterial toxins and prevent their harmful effects by providing immediate passive immunity against pathogens, is expected to drive the axillary hyperhidrosis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the axillary hyperhidrosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for axillary hyperhidrosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the axillary hyperhidrosis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the axillary hyperhidrosis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the axillary hyperhidrosis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current axillary hyperhidrosis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the axillary hyperhidrosis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the axillary hyperhidrosis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the axillary hyperhidrosis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of axillary hyperhidrosis across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of axillary hyperhidrosis by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of axillary hyperhidrosis by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with axillary hyperhidrosis across the seven major markets?
What is the size of the axillary hyperhidrosis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of axillary hyperhidrosis?
What will be the growth rate of patients across the seven major markets?
Axillary Hyperhidrosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for axillary hyperhidrosis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the axillary hyperhidrosis market?
What are the key regulatory events related to the axillary hyperhidrosis market?
What is the structure of clinical trial landscape by status related to the axillary hyperhidrosis market?
What is the structure of clinical trial landscape by phase related to the axillary hyperhidrosis market?
What is the structure of clinical trial landscape by route of administration related to the axillary hyperhidrosis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 AXILLARY HYPERHIDROSIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 AXILLARY HYPERHIDROSIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 AXILLARY HYPERHIDROSIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 AXILLARY HYPERHIDROSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 AXILLARY HYPERHIDROSIS - UNMET NEEDS
10 AXILLARY HYPERHIDROSIS - KEY ENDPOINTS OF TREATMENT
11 AXILLARY HYPERHIDROSIS - MARKETED PRODUCTS
11.1 List of Axillary Hyperhidrosis Marketed Drugs Across the Top 7 Markets
11.1.1 Botox (Onabotulinumtoxin A)- Abbvie
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Qbrexza (Glycopyrronium)- Dermira
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 AXILLARY HYPERHIDROSIS - PIPELINE DRUGS
12.1 List of Axillary Hyperhidrosis Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. AXILLARY HYPERHIDROSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. AXILLARY HYPERHIDROSIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 AXILLARY HYPERHIDROSIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Axillary Hyperhidrosis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Axillary Hyperhidrosis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Axillary Hyperhidrosis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Axillary Hyperhidrosis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Axillary Hyperhidrosis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Axillary Hyperhidrosis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Axillary Hyperhidrosis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Axillary Hyperhidrosis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Axillary Hyperhidrosis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Axillary Hyperhidrosis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Axillary Hyperhidrosis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Axillary Hyperhidrosis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Axillary Hyperhidrosis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Axillary Hyperhidrosis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Axillary Hyperhidrosis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Axillary Hyperhidrosis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Axillary Hyperhidrosis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Axillary Hyperhidrosis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Axillary Hyperhidrosis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Axillary Hyperhidrosis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Axillary Hyperhidrosis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Axillary Hyperhidrosis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Axillary Hyperhidrosis - Access and Reimbursement Overview
16 AXILLARY HYPERHIDROSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 AXILLARY HYPERHIDROSIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 AXILLARY HYPERHIDROSIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 AXILLARY HYPERHIDROSIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 AXILLARY HYPERHIDROSIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 AXILLARY HYPERHIDROSIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 AXILLARY HYPERHIDROSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 AXILLARY HYPERHIDROSIS - UNMET NEEDS
10 AXILLARY HYPERHIDROSIS - KEY ENDPOINTS OF TREATMENT
11 AXILLARY HYPERHIDROSIS - MARKETED PRODUCTS
11.1 List of Axillary Hyperhidrosis Marketed Drugs Across the Top 7 Markets
11.1.1 Botox (Onabotulinumtoxin A)- Abbvie
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Qbrexza (Glycopyrronium)- Dermira
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 AXILLARY HYPERHIDROSIS - PIPELINE DRUGS
12.1 List of Axillary Hyperhidrosis Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. AXILLARY HYPERHIDROSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. AXILLARY HYPERHIDROSIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 AXILLARY HYPERHIDROSIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Axillary Hyperhidrosis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Axillary Hyperhidrosis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Axillary Hyperhidrosis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Axillary Hyperhidrosis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Axillary Hyperhidrosis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Axillary Hyperhidrosis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Axillary Hyperhidrosis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Axillary Hyperhidrosis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Axillary Hyperhidrosis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Axillary Hyperhidrosis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Axillary Hyperhidrosis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Axillary Hyperhidrosis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Axillary Hyperhidrosis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Axillary Hyperhidrosis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Axillary Hyperhidrosis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Axillary Hyperhidrosis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Axillary Hyperhidrosis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Axillary Hyperhidrosis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Axillary Hyperhidrosis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Axillary Hyperhidrosis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Axillary Hyperhidrosis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Axillary Hyperhidrosis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Axillary Hyperhidrosis - Access and Reimbursement Overview
16 AXILLARY HYPERHIDROSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 AXILLARY HYPERHIDROSIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 AXILLARY HYPERHIDROSIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
